Navigation Links
GUMC discovery highlights new direction for drug discovery
Date:7/5/2009

Washington, DC In a discovery that rebuffs conventional scientific thinking, researchers at Georgetown University Medical Center (GUMC) have discovered a novel way to block the activity of the fusion protein responsible for Ewing's sarcoma, a rare cancer found in children and young adults.

In the paper published online July 5 in Nature Medicine, they report discovering and successfully testing a small molecule that keeps the fusion protein from sticking to another protein that is critical for tumor formation. The researchers say this interaction is unique and is especially surprising since the Ewing's sarcoma fusion protein is extremely flexible, which allows it to change shape constantly.

"Most targeted small molecule cancer drugs inhibit the intrinsic activity of a single protein, but our agent stops two proteins from interacting. This has never been shown before with a cancer-causing fusion protein and represents a potentially novel medical therapy in the future," says the study's lead investigator, Jeffrey Toretsky, MD, a pediatric oncology physician and researcher at GUMC's Lombardi Comprehensive Cancer Center.

The study could provide a model upon which to design treatment for other disorders caused by the interaction between two proteins, and may be especially useful in cancers caused by translocations of genes, such as sarcomas and leukemias, the researchers say. Agents in use now that work against fusion proteins inhibit a single protein to stop intrinsic enzymatic activity; one example is Gleevec, used for chronic myelogenous leukemia (CML). The Ewing's sarcoma fusion protein, known as EWS-FLI1, lacks enzymatic activity, "and this difference is why our work is significant," Toretsky says.

In the United States, about 500 patients annually are diagnosed with the cancer, and they are treated with a combination of five different chemotherapy drugs. Between 60-70 percent of patients survive over time, but with
'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Discovery may provide new treatments for alcohol dependence
2. New nanoparticles could revolutionize therapeutic drug discovery
3. Discovery of a water snake that startles fish in a way that makes them flee into its jaws
4. New discovery suggests mammoths survived in Britain until 14,000 years ago
5. Discovery of the cells water gate may lead to new cancer drugs
6. Aussie and Kiwi researchers make double MS genetic discovery
7. Discovery raises new doubts about dinosaur-bird links
8. NAU discovery could help feed millions
9. Voyages of discovery or necessity?
10. NASA Earth system science meeting celebrates 20 years of discovery
11. Cells split personality is a major discovery into neurological diseases
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 1GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 2GSK Limits Medical Education Funding to Independent Programs With Highest Impact on Patient Care 57764 3ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 1ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 2ANAVEX completes scale up manufacturing of ANAVEX 2 73 for Phase I Alzheimers disease clinical trials 5022 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 1With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 2With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 4With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 5With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 6
Breaking Biology Technology:Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4